SRT3

231.9

+0.69%↑

GXI

54.3

+2.74%↑

ICAD

21

-1.5%↓

SRT3

231.9

+0.69%↑

GXI

54.3

+2.74%↑

ICAD

21

-1.5%↓

SRT3

231.9

+0.69%↑

GXI

54.3

+2.74%↑

ICAD

21

-1.5%↓

SRT3

231.9

+0.69%↑

GXI

54.3

+2.74%↑

ICAD

21

-1.5%↓

SRT3

231.9

+0.69%↑

GXI

54.3

+2.74%↑

ICAD

21

-1.5%↓

Search

BioMerieux

Avatud

SektorTervishoid

115.1 1.32

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

113.3

Max

115.2

Põhinäitajad

By Trading Economics

Sissetulek

215M

Müük

785M

P/E

Sektori keskmine

31.236

57.333

Dividenditootlus

0.79

Kasumimarginaal

11.32

Töötajad

14,147

EBITDA

161M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+16.61% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.79%

2.63%

Turustatistika

By TradingEconomics

Turukapital

-117M

13B

Eelmine avamishind

113.78

Eelmine sulgemishind

115.1

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

BioMerieux Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. apr 2025, 08:49 UTC

Suurimad hinnamuutused turgudel

BioMerieux Shares Fall After Warning on Currency-Exchange Hit

Võrdlus sarnastega

Hinnamuutus

BioMerieux Prognoos

Hinnasiht

By TipRanks

16.61% tõus

12 kuu keskmine prognoos

Keskmine 133.17 EUR  16.61%

Kõrge 140 EUR

Madal 127 EUR

Põhineb 6 Wall Streeti analüütiku instrumendi BioMerieux 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

113.8 / 118.9Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioMerieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.